SCHEMBL22160861

SCHEMBL22160861

O=C(O)c1ccc(C(=O)O)c(CNc2ccc3[nH]c(=O)[nH]c3c2)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.54
▸ GAA P10253 7/20 0.54
▸ BCL6 P41182 1/20 0.54
▸ BCOR Q6W2J9 1/20 0.54
▸ KDM4E B2RXH2 7/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ MAPK1 P28482 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ GFER P55789 1/20 0.48
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ G6PD P11413 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ BLM P54132 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29260536 0.91 MAPT (0.51) MAPTGAABCL6BCORKDM4E
SCHEMBL29260532 0.88 GAA (0.64) MAPTGAABCL6BCORKDM4E
SCHEMBL20772803 0.83 BCL6 (0.56) MAPTGAABCL6BCORKDM4E
SCHEMBL29857819 0.83 BCL6 (0.56) MAPTGAABCL6BCORKDM4E
SCHEMBL29280284 0.79 BCL6 (0.70) MAPTBCL6BCORKDM4EL3MBTL1
SCHEMBL29280285 0.79 BCL6 (0.70) MAPTBCL6BCORKDM4EL3MBTL1
SCHEMBL1095502 0.75 SIRT2 (0.69) MAPTGAABCL6BCORKDM4E
SCHEMBL20773158 0.75 GAA (0.70) MAPTGAAKDM4EPOLBALDH1A1
SCHEMBL22425303 0.72 MAPT (0.64) MAPTGAABCL6BCORKDM4E
SCHEMBL30832906 0.71 BCL6 (0.63) MAPTGAABCL6BCORKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-04-04 — — US disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2022-09-15 — — US disclosed
US-11254672-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2022-02-22 — — US disclosed
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MAPT 2761/4885GAA 1982/4885BCL6 427/4885
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MAPT 2761/4885GAA 1982/4885BCL6 427/4885
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MAPT 2761/4885GAA 1982/4885BCL6 427/4885
US-11787802-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 MAPT 2761/4885GAA 1982/4885BCL6 427/4885
US-11254672-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 MAPT 2761/4885GAA 1982/4885BCL6 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback